Achieve Life Sciences, Inc. has reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $40.0 million for the nine months ended September 30, 2025, compared to a net loss of $27.5 million for the same period in 2024. This increase in losses is attributed to higher research and development expenses, particularly related to the ORCA-OL trial, which was completed in September 2025. The company’s accumulated deficit has now reached $245.6 million, with cash, cash equivalents, and marketable securities totaling $48.1 million as of the end of the reporting period.
In terms of operational changes, Achieve Life Sciences has made strides in its clinical development of cytisinicline, a product candidate aimed at addressing nicotine dependence. The FDA accepted the company's New Drug Application (NDA) for cytisinicline in September 2025, with a Prescription Drug User Fee Act (PDUFA) target action date set for June 20, 2026. The company has also received Breakthrough Therapy designation for cytisinicline for vaping cessation, which is expected to expedite its development and review process. However, Achieve Life Sciences faces ongoing challenges, including a dispute with its supplier, Sopharma, regarding manufacturing capabilities and compliance with FDA regulations.
The company’s financial position reflects a reliance on external funding, as it has not generated revenue from product sales to date. Achieve Life Sciences has historically financed its operations through equity offerings and debt financing, and it anticipates needing to raise additional capital to support its ongoing clinical development and commercialization efforts. The recent June 2025 public offering raised approximately $41.2 million, which will be crucial for funding its operations into the second half of 2026. However, the company has expressed substantial doubt about its ability to continue as a going concern without securing further financing.
Achieve Life Sciences has also reported an increase in general and administrative expenses, which rose to $21.0 million for the nine months ended September 30, 2025, compared to $11.4 million for the same period in 2024. This increase is primarily due to higher costs associated with commercial launch preparations and employee compensation. The company’s workforce has expanded, reflecting its efforts to build a commercial infrastructure in anticipation of potential product approval.
Looking ahead, Achieve Life Sciences is focused on the successful commercialization of cytisinicline, pending regulatory approval. The company plans to leverage its marketing technology infrastructure and AI tools to enhance its marketing efforts. However, it acknowledges the inherent risks associated with drug development, including competition from established products and the need for effective reimbursement strategies. The company remains committed to addressing the global nicotine dependence epidemic and is preparing for a potential product launch in the second half of 2026, contingent upon successful regulatory outcomes.
About ACHIEVE LIFE SCIENCES, INC.
Achieve Life Sciences, Inc. is a late-stage clinical specialty pharmaceutical company dedicated to combating nicotine dependence through its product candidate, cytisinicline. Targeting the 29 million U.S. smokers and 11 million e-cigarette users, Achieve aims to address a significant health crisis. With FDA Breakthrough Therapy Designation, cytisinicline is positioned to become the first new prescription treatment for smoking cessation in nearly two decades, offering a promising solution with a favorable safety profile.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.